Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370879 | 0.81 | MEN1 (0.33) | MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL7708604 | 0.79 | MEN1 (0.32) | MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL16357610 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL81885 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL10749460 | 0.76 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL8414663 | 0.76 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9067505 | 0.76 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL5801785 | 0.76 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL13734363 | 0.75 | MEN1 (0.31) | MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL11466419 | 0.75 | MEN1 (0.42) | ALDH1A1MEN1KMT2ACYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | claimed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | claimed |
| EP-1390337-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | Givaudan SA (CH) | 2004-02-25 | — | — | EP | claimed |
| WO-2002096850-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | GIVAUDAN SA (CH) | 2002-12-05 | — | — | WO | claimed |
| EP-1262473-A1 | Precursors for fragrant ketones and fragrant aldehydes | Givaudan SA (CH) | 2002-12-04 | — | — | EP | claimed |
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | disclosed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | disclosed |
| EP-1262473-A1 | Precursors for fragrant ketones and fragrant aldehydes | Givaudan SA (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-4226765-A | Novel rifamycin compounds of high antibiotic activity | ARCHIFAR INDUSTRIE CHIMICHE DEL TRENTINO S.P.A. (IT) | 1980-10-07 | — | — | US | disclosed |
| US-4194045-A | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds | G. D. SEARLE & CO. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4194045-A | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds | G. D. SEARLE & CO. (US) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171516-A1 | Precursors for ketones and aldehydes | PDK3, PDK4, AKR1C4 | ALDH1A1 13/4885MEN1 3742/4885KMT2A 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.